Analysis of survival differences in advanced triple-negative breast cancer: a real-world study Article Swipe
Junsheng Zheng
,
Xiaowen Wang
,
Zhiqiang Shi
,
Zhao Bi
,
Yongsheng Wang
,
Pengfei Qiu
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fonc.2025.1635243
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fonc.2025.1635243
Background Advanced triple-negative breast cancer (aTNBC) has a poor prognosis, and there is a dearth of relevant real-world research data. This study is aimed at analyzing the survival outcomes and subgroup characteristics of aTNBC in the first-line treatment stage, providing data support for clinical treatment decisions. Methods A retrospective analysis was conducted on 215 patients with aTNBC who received first-line salvage treatment at Shandong Cancer Hospital from January 2018 to March 2023 (74 patients of de novo metastatic breast cancer [dnMBC] and 141 patients of recurrent metastatic breast cancer [rMBC]). Progression-free survival (PFS) and overall survival (OS) were assessed using the Kaplan-Meier method, and hazard ratio (HR) were calculated using the Cox regression model. Spearman correlation analysis was used to evaluate the relationship between PFS and OS. Results The median PFS for aTNBC patients during the first-line treatment phase was 8.40 months (95% CI: 7.56–9.24 months), while the median OS was 23.87 months (95% CI: 20.53–27.21 months). Multivariate Cox regression and interaction analyses identified several independent prognostic factors affecting PFS, including dnMBC, platinum-containing regimen, immunotherapy, and local treatment of metastasis. For OS, independent prognostic factors included dnMBC, G3, and platinum-containing regimen. Additional survival analysis showed that the risk of disease progression and death was significantly lower in dnMBC patients compared to rMBC patients (PFS: HR = 0.70, 95% CI: 0.51-0.95, P = 0.025; OS: HR = 0.65, 95% CI: 0.45-0.95, P = 0.023). Furthermore, in both groups, PFS and OS were positively correlated ( r s = 0.54; r s = 0.58). Conclusion In patients with aTNBC, those with dnMBC demonstrate a more pronounced survival benefit, with this advantage being consistent across various clinicopathological parameters. Therefore, stratifying patients by metastatic category in clinical trials may improve evaluation of treatment efficacy and support more individualized patient management.
Related Topics
Concepts
Medicine
Internal medicine
Hazard ratio
Regimen
Oncology
Proportional hazards model
Breast cancer
Metastatic breast cancer
Multivariate analysis
Retrospective cohort study
Progression-free survival
Triple-negative breast cancer
Cancer
Confidence interval
Overall survival
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fonc.2025.1635243
- https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdf
- OA Status
- gold
- References
- 37
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4413381825
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4413381825Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fonc.2025.1635243Digital Object Identifier
- Title
-
Analysis of survival differences in advanced triple-negative breast cancer: a real-world studyWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-08-15Full publication date if available
- Authors
-
Junsheng Zheng, Xiaowen Wang, Zhiqiang Shi, Zhao Bi, Yongsheng Wang, Pengfei QiuList of authors in order
- Landing page
-
https://doi.org/10.3389/fonc.2025.1635243Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdfDirect OA link when available
- Concepts
-
Medicine, Internal medicine, Hazard ratio, Regimen, Oncology, Proportional hazards model, Breast cancer, Metastatic breast cancer, Multivariate analysis, Retrospective cohort study, Progression-free survival, Triple-negative breast cancer, Cancer, Confidence interval, Overall survivalTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
37Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4413381825 |
|---|---|
| doi | https://doi.org/10.3389/fonc.2025.1635243 |
| ids.doi | https://doi.org/10.3389/fonc.2025.1635243 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40896426 |
| ids.openalex | https://openalex.org/W4413381825 |
| fwci | 0.0 |
| type | article |
| title | Analysis of survival differences in advanced triple-negative breast cancer: a real-world study |
| biblio.issue | |
| biblio.volume | 15 |
| biblio.last_page | 1635243 |
| biblio.first_page | 1635243 |
| topics[0].id | https://openalex.org/T11287 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9998000264167786 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1306 |
| topics[0].subfield.display_name | Cancer Research |
| topics[0].display_name | Cancer Genomics and Diagnostics |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9994999766349792 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T10183 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9993000030517578 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Breast Cancer Treatment Studies |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8838554620742798 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C126322002 |
| concepts[1].level | 1 |
| concepts[1].score | 0.7596372961997986 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[1].display_name | Internal medicine |
| concepts[2].id | https://openalex.org/C207103383 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6984467506408691 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[2].display_name | Hazard ratio |
| concepts[3].id | https://openalex.org/C2781413609 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6674026250839233 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7308373 |
| concepts[3].display_name | Regimen |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6640109419822693 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C50382708 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6345605850219727 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q223218 |
| concepts[5].display_name | Proportional hazards model |
| concepts[6].id | https://openalex.org/C530470458 |
| concepts[6].level | 3 |
| concepts[6].score | 0.6313164234161377 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128581 |
| concepts[6].display_name | Breast cancer |
| concepts[7].id | https://openalex.org/C2775930923 |
| concepts[7].level | 4 |
| concepts[7].score | 0.618546187877655 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12859063 |
| concepts[7].display_name | Metastatic breast cancer |
| concepts[8].id | https://openalex.org/C38180746 |
| concepts[8].level | 2 |
| concepts[8].score | 0.48313090205192566 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1952580 |
| concepts[8].display_name | Multivariate analysis |
| concepts[9].id | https://openalex.org/C167135981 |
| concepts[9].level | 2 |
| concepts[9].score | 0.43344438076019287 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2146302 |
| concepts[9].display_name | Retrospective cohort study |
| concepts[10].id | https://openalex.org/C2780739268 |
| concepts[10].level | 3 |
| concepts[10].score | 0.42662903666496277 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2112244 |
| concepts[10].display_name | Progression-free survival |
| concepts[11].id | https://openalex.org/C2780110267 |
| concepts[11].level | 4 |
| concepts[11].score | 0.4127345085144043 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7843332 |
| concepts[11].display_name | Triple-negative breast cancer |
| concepts[12].id | https://openalex.org/C121608353 |
| concepts[12].level | 2 |
| concepts[12].score | 0.41248947381973267 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[12].display_name | Cancer |
| concepts[13].id | https://openalex.org/C44249647 |
| concepts[13].level | 2 |
| concepts[13].score | 0.25032106041908264 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[13].display_name | Confidence interval |
| concepts[14].id | https://openalex.org/C3019894029 |
| concepts[14].level | 2 |
| concepts[14].score | 0.24276849627494812 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q332823 |
| concepts[14].display_name | Overall survival |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8838554620742798 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/internal-medicine |
| keywords[1].score | 0.7596372961997986 |
| keywords[1].display_name | Internal medicine |
| keywords[2].id | https://openalex.org/keywords/hazard-ratio |
| keywords[2].score | 0.6984467506408691 |
| keywords[2].display_name | Hazard ratio |
| keywords[3].id | https://openalex.org/keywords/regimen |
| keywords[3].score | 0.6674026250839233 |
| keywords[3].display_name | Regimen |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.6640109419822693 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/proportional-hazards-model |
| keywords[5].score | 0.6345605850219727 |
| keywords[5].display_name | Proportional hazards model |
| keywords[6].id | https://openalex.org/keywords/breast-cancer |
| keywords[6].score | 0.6313164234161377 |
| keywords[6].display_name | Breast cancer |
| keywords[7].id | https://openalex.org/keywords/metastatic-breast-cancer |
| keywords[7].score | 0.618546187877655 |
| keywords[7].display_name | Metastatic breast cancer |
| keywords[8].id | https://openalex.org/keywords/multivariate-analysis |
| keywords[8].score | 0.48313090205192566 |
| keywords[8].display_name | Multivariate analysis |
| keywords[9].id | https://openalex.org/keywords/retrospective-cohort-study |
| keywords[9].score | 0.43344438076019287 |
| keywords[9].display_name | Retrospective cohort study |
| keywords[10].id | https://openalex.org/keywords/progression-free-survival |
| keywords[10].score | 0.42662903666496277 |
| keywords[10].display_name | Progression-free survival |
| keywords[11].id | https://openalex.org/keywords/triple-negative-breast-cancer |
| keywords[11].score | 0.4127345085144043 |
| keywords[11].display_name | Triple-negative breast cancer |
| keywords[12].id | https://openalex.org/keywords/cancer |
| keywords[12].score | 0.41248947381973267 |
| keywords[12].display_name | Cancer |
| keywords[13].id | https://openalex.org/keywords/confidence-interval |
| keywords[13].score | 0.25032106041908264 |
| keywords[13].display_name | Confidence interval |
| keywords[14].id | https://openalex.org/keywords/overall-survival |
| keywords[14].score | 0.24276849627494812 |
| keywords[14].display_name | Overall survival |
| language | en |
| locations[0].id | doi:10.3389/fonc.2025.1635243 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S2596394214 |
| locations[0].source.issn | 2234-943X |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2234-943X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Oncology |
| locations[0].landing_page_url | https://doi.org/10.3389/fonc.2025.1635243 |
| locations[1].id | pmid:40896426 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in oncology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40896426 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:12394513 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Front Oncol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12394513 |
| locations[3].id | pmh:oai:doaj.org/article:5bd3c5cd01154e05ac6713fe904cc691 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306401280 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[3].source.host_organization | |
| locations[3].source.host_organization_name | |
| locations[3].source.host_organization_lineage | |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | article |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | Frontiers in Oncology, Vol 15 (2025) |
| locations[3].landing_page_url | https://doaj.org/article/5bd3c5cd01154e05ac6713fe904cc691 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5111628069 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Junsheng Zheng |
| authorships[0].countries | CN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[0].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[0].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[0].institutions[0].country_code | CN |
| authorships[0].institutions[0].display_name | Shandong First Medical University |
| authorships[0].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[0].institutions[1].ror | https://ror.org/01413r497 |
| authorships[0].institutions[1].type | healthcare |
| authorships[0].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[0].institutions[1].country_code | CN |
| authorships[0].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Jun-Sheng Zheng |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[1].author.id | https://openalex.org/A5100454354 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4623-1608 |
| authorships[1].author.display_name | Xiaowen Wang |
| authorships[1].countries | CN |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[1].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[1].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[1].institutions[0].country_code | CN |
| authorships[1].institutions[0].display_name | Shandong First Medical University |
| authorships[1].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[1].institutions[1].ror | https://ror.org/01413r497 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[1].institutions[1].country_code | CN |
| authorships[1].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Xiao-Wen Wang |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[2].author.id | https://openalex.org/A5048389776 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-8223-2766 |
| authorships[2].author.display_name | Zhiqiang Shi |
| authorships[2].countries | CN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[2].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[2].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[2].institutions[0].country_code | CN |
| authorships[2].institutions[0].display_name | Shandong First Medical University |
| authorships[2].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[2].institutions[1].ror | https://ror.org/01413r497 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[2].institutions[1].country_code | CN |
| authorships[2].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Zhi-Qiang Shi |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[3].author.id | https://openalex.org/A5059366112 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9546-1704 |
| authorships[3].author.display_name | Zhao Bi |
| authorships[3].countries | CN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[3].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[3].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[3].institutions[0].country_code | CN |
| authorships[3].institutions[0].display_name | Shandong First Medical University |
| authorships[3].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[3].institutions[1].ror | https://ror.org/01413r497 |
| authorships[3].institutions[1].type | healthcare |
| authorships[3].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[3].institutions[1].country_code | CN |
| authorships[3].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Zhao Bi |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[4].author.id | https://openalex.org/A5100360006 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-3673-8376 |
| authorships[4].author.display_name | Yongsheng Wang |
| authorships[4].countries | CN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[4].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[4].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[4].institutions[0].country_code | CN |
| authorships[4].institutions[0].display_name | Shandong First Medical University |
| authorships[4].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[4].institutions[1].ror | https://ror.org/01413r497 |
| authorships[4].institutions[1].type | healthcare |
| authorships[4].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[4].institutions[1].country_code | CN |
| authorships[4].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Yong-Sheng Wang |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[5].author.id | https://openalex.org/A5033087015 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-6784-410X |
| authorships[5].author.display_name | Pengfei Qiu |
| authorships[5].countries | CN |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| authorships[5].institutions[0].id | https://openalex.org/I4210163399 |
| authorships[5].institutions[0].ror | https://ror.org/05jb9pq57 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210163399 |
| authorships[5].institutions[0].country_code | CN |
| authorships[5].institutions[0].display_name | Shandong First Medical University |
| authorships[5].institutions[1].id | https://openalex.org/I4210100830 |
| authorships[5].institutions[1].ror | https://ror.org/01413r497 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I4210100830 |
| authorships[5].institutions[1].country_code | CN |
| authorships[5].institutions[1].display_name | Shandong Tumor Hospital |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Peng-Fei Qiu |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Department of Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Analysis of survival differences in advanced triple-negative breast cancer: a real-world study |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11287 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9998000264167786 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1306 |
| primary_topic.subfield.display_name | Cancer Research |
| primary_topic.display_name | Cancer Genomics and Diagnostics |
| related_works | https://openalex.org/W1535396021, https://openalex.org/W4362432751, https://openalex.org/W3203106735, https://openalex.org/W4367666111, https://openalex.org/W2800306828, https://openalex.org/W4323532697, https://openalex.org/W2128571346, https://openalex.org/W3006098800, https://openalex.org/W1973504138, https://openalex.org/W2945426176 |
| cited_by_count | 0 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fonc.2025.1635243 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2596394214 |
| best_oa_location.source.issn | 2234-943X |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2234-943X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fonc.2025.1635243 |
| primary_location.id | doi:10.3389/fonc.2025.1635243 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S2596394214 |
| primary_location.source.issn | 2234-943X |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2234-943X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1635243/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Oncology |
| primary_location.landing_page_url | https://doi.org/10.3389/fonc.2025.1635243 |
| publication_date | 2025-08-15 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2912993657, https://openalex.org/W2151929173, https://openalex.org/W2306874502, https://openalex.org/W4390670334, https://openalex.org/W4378781718, https://openalex.org/W4223431729, https://openalex.org/W2111495238, https://openalex.org/W2140365771, https://openalex.org/W4283073105, https://openalex.org/W3092178700, https://openalex.org/W2788113610, https://openalex.org/W2979515484, https://openalex.org/W1964554229, https://openalex.org/W4323665197, https://openalex.org/W4407165123, https://openalex.org/W4293072485, https://openalex.org/W4323532697, https://openalex.org/W2603868227, https://openalex.org/W3128102585, https://openalex.org/W3099852086, https://openalex.org/W4387349539, https://openalex.org/W2617760410, https://openalex.org/W2150575159, https://openalex.org/W2476568892, https://openalex.org/W2001710411, https://openalex.org/W3111153505, https://openalex.org/W4404038859, https://openalex.org/W4385308490, https://openalex.org/W2142226415, https://openalex.org/W2806830990, https://openalex.org/W4285093997, https://openalex.org/W3037754071, https://openalex.org/W1801537031, https://openalex.org/W2897422388, https://openalex.org/W3175173749, https://openalex.org/W3109853980, https://openalex.org/W4393935425 |
| referenced_works_count | 37 |
| abstract_inverted_index.( | 243 |
| abstract_inverted_index.= | 215, 221, 225, 231, 246, 250 |
| abstract_inverted_index.A | 47 |
| abstract_inverted_index.P | 220, 230 |
| abstract_inverted_index.a | 7, 13, 261 |
| abstract_inverted_index.r | 244, 248 |
| abstract_inverted_index.s | 245, 249 |
| abstract_inverted_index.HR | 214, 224 |
| abstract_inverted_index.In | 253 |
| abstract_inverted_index.OS | 149, 239 |
| abstract_inverted_index.at | 24, 62 |
| abstract_inverted_index.by | 278 |
| abstract_inverted_index.de | 75 |
| abstract_inverted_index.in | 34, 206, 234, 281 |
| abstract_inverted_index.is | 12, 22 |
| abstract_inverted_index.of | 15, 32, 74, 84, 178, 198, 287 |
| abstract_inverted_index.on | 52 |
| abstract_inverted_index.to | 69, 119, 210 |
| abstract_inverted_index.(74 | 72 |
| abstract_inverted_index.141 | 82 |
| abstract_inverted_index.215 | 53 |
| abstract_inverted_index.95% | 217, 227 |
| abstract_inverted_index.CI: | 143, 154, 218, 228 |
| abstract_inverted_index.Cox | 111, 158 |
| abstract_inverted_index.For | 180 |
| abstract_inverted_index.G3, | 187 |
| abstract_inverted_index.OS, | 181 |
| abstract_inverted_index.OS. | 126 |
| abstract_inverted_index.OS: | 223 |
| abstract_inverted_index.PFS | 124, 130, 237 |
| abstract_inverted_index.The | 128 |
| abstract_inverted_index.and | 10, 29, 81, 93, 103, 125, 160, 175, 188, 201, 238, 290 |
| abstract_inverted_index.for | 42, 131 |
| abstract_inverted_index.has | 6 |
| abstract_inverted_index.may | 284 |
| abstract_inverted_index.the | 26, 35, 100, 110, 121, 135, 147, 196 |
| abstract_inverted_index.was | 50, 117, 139, 150, 203 |
| abstract_inverted_index.who | 57 |
| abstract_inverted_index.(95% | 142, 153 |
| abstract_inverted_index.(HR) | 106 |
| abstract_inverted_index.(OS) | 96 |
| abstract_inverted_index.2018 | 68 |
| abstract_inverted_index.2023 | 71 |
| abstract_inverted_index.8.40 | 140 |
| abstract_inverted_index.PFS, | 169 |
| abstract_inverted_index.This | 20 |
| abstract_inverted_index.both | 235 |
| abstract_inverted_index.data | 40 |
| abstract_inverted_index.from | 66 |
| abstract_inverted_index.more | 262, 292 |
| abstract_inverted_index.novo | 76 |
| abstract_inverted_index.poor | 8 |
| abstract_inverted_index.rMBC | 211 |
| abstract_inverted_index.risk | 197 |
| abstract_inverted_index.that | 195 |
| abstract_inverted_index.this | 267 |
| abstract_inverted_index.used | 118 |
| abstract_inverted_index.were | 97, 107, 240 |
| abstract_inverted_index.with | 55, 255, 258, 266 |
| abstract_inverted_index.(PFS) | 92 |
| abstract_inverted_index.(PFS: | 213 |
| abstract_inverted_index.0.54; | 247 |
| abstract_inverted_index.0.65, | 226 |
| abstract_inverted_index.0.70, | 216 |
| abstract_inverted_index.23.87 | 151 |
| abstract_inverted_index.March | 70 |
| abstract_inverted_index.aTNBC | 33, 56, 132 |
| abstract_inverted_index.aimed | 23 |
| abstract_inverted_index.being | 269 |
| abstract_inverted_index.data. | 19 |
| abstract_inverted_index.death | 202 |
| abstract_inverted_index.dnMBC | 207, 259 |
| abstract_inverted_index.local | 176 |
| abstract_inverted_index.lower | 205 |
| abstract_inverted_index.phase | 138 |
| abstract_inverted_index.ratio | 105 |
| abstract_inverted_index.study | 21 |
| abstract_inverted_index.there | 11 |
| abstract_inverted_index.those | 257 |
| abstract_inverted_index.using | 99, 109 |
| abstract_inverted_index.while | 146 |
| abstract_inverted_index.0.025; | 222 |
| abstract_inverted_index.0.58). | 251 |
| abstract_inverted_index.Cancer | 64 |
| abstract_inverted_index.aTNBC, | 256 |
| abstract_inverted_index.across | 271 |
| abstract_inverted_index.breast | 3, 78, 87 |
| abstract_inverted_index.cancer | 4, 79, 88 |
| abstract_inverted_index.dearth | 14 |
| abstract_inverted_index.dnMBC, | 171, 186 |
| abstract_inverted_index.during | 134 |
| abstract_inverted_index.hazard | 104 |
| abstract_inverted_index.median | 129, 148 |
| abstract_inverted_index.model. | 113 |
| abstract_inverted_index.months | 141, 152 |
| abstract_inverted_index.showed | 194 |
| abstract_inverted_index.stage, | 38 |
| abstract_inverted_index.trials | 283 |
| abstract_inverted_index.(aTNBC) | 5 |
| abstract_inverted_index.0.023). | 232 |
| abstract_inverted_index.January | 67 |
| abstract_inverted_index.Methods | 46 |
| abstract_inverted_index.Results | 127 |
| abstract_inverted_index.[dnMBC] | 80 |
| abstract_inverted_index.between | 123 |
| abstract_inverted_index.disease | 199 |
| abstract_inverted_index.factors | 167, 184 |
| abstract_inverted_index.groups, | 236 |
| abstract_inverted_index.improve | 285 |
| abstract_inverted_index.method, | 102 |
| abstract_inverted_index.overall | 94 |
| abstract_inverted_index.patient | 294 |
| abstract_inverted_index.salvage | 60 |
| abstract_inverted_index.several | 164 |
| abstract_inverted_index.support | 41, 291 |
| abstract_inverted_index.various | 272 |
| abstract_inverted_index.Advanced | 1 |
| abstract_inverted_index.Hospital | 65 |
| abstract_inverted_index.Shandong | 63 |
| abstract_inverted_index.Spearman | 114 |
| abstract_inverted_index.[rMBC]). | 89 |
| abstract_inverted_index.analyses | 162 |
| abstract_inverted_index.analysis | 49, 116, 193 |
| abstract_inverted_index.assessed | 98 |
| abstract_inverted_index.benefit, | 265 |
| abstract_inverted_index.category | 280 |
| abstract_inverted_index.clinical | 43, 282 |
| abstract_inverted_index.compared | 209 |
| abstract_inverted_index.efficacy | 289 |
| abstract_inverted_index.evaluate | 120 |
| abstract_inverted_index.included | 185 |
| abstract_inverted_index.months), | 145 |
| abstract_inverted_index.months). | 156 |
| abstract_inverted_index.outcomes | 28 |
| abstract_inverted_index.patients | 54, 73, 83, 133, 208, 212, 254, 277 |
| abstract_inverted_index.received | 58 |
| abstract_inverted_index.regimen, | 173 |
| abstract_inverted_index.regimen. | 190 |
| abstract_inverted_index.relevant | 16 |
| abstract_inverted_index.research | 18 |
| abstract_inverted_index.subgroup | 30 |
| abstract_inverted_index.survival | 27, 91, 95, 192, 264 |
| abstract_inverted_index.advantage | 268 |
| abstract_inverted_index.affecting | 168 |
| abstract_inverted_index.analyzing | 25 |
| abstract_inverted_index.conducted | 51 |
| abstract_inverted_index.including | 170 |
| abstract_inverted_index.providing | 39 |
| abstract_inverted_index.recurrent | 85 |
| abstract_inverted_index.treatment | 37, 44, 61, 137, 177, 288 |
| abstract_inverted_index.0.45-0.95, | 229 |
| abstract_inverted_index.0.51-0.95, | 219 |
| abstract_inverted_index.Additional | 191 |
| abstract_inverted_index.Background | 0 |
| abstract_inverted_index.Conclusion | 252 |
| abstract_inverted_index.Therefore, | 275 |
| abstract_inverted_index.calculated | 108 |
| abstract_inverted_index.consistent | 270 |
| abstract_inverted_index.correlated | 242 |
| abstract_inverted_index.decisions. | 45 |
| abstract_inverted_index.evaluation | 286 |
| abstract_inverted_index.first-line | 36, 59, 136 |
| abstract_inverted_index.identified | 163 |
| abstract_inverted_index.metastatic | 77, 86, 279 |
| abstract_inverted_index.positively | 241 |
| abstract_inverted_index.prognosis, | 9 |
| abstract_inverted_index.prognostic | 166, 183 |
| abstract_inverted_index.pronounced | 263 |
| abstract_inverted_index.real-world | 17 |
| abstract_inverted_index.regression | 112, 159 |
| abstract_inverted_index.7.56–9.24 | 144 |
| abstract_inverted_index.correlation | 115 |
| abstract_inverted_index.demonstrate | 260 |
| abstract_inverted_index.independent | 165, 182 |
| abstract_inverted_index.interaction | 161 |
| abstract_inverted_index.management. | 295 |
| abstract_inverted_index.metastasis. | 179 |
| abstract_inverted_index.parameters. | 274 |
| abstract_inverted_index.progression | 200 |
| abstract_inverted_index.stratifying | 276 |
| abstract_inverted_index.Furthermore, | 233 |
| abstract_inverted_index.Kaplan-Meier | 101 |
| abstract_inverted_index.Multivariate | 157 |
| abstract_inverted_index.relationship | 122 |
| abstract_inverted_index.20.53–27.21 | 155 |
| abstract_inverted_index.retrospective | 48 |
| abstract_inverted_index.significantly | 204 |
| abstract_inverted_index.immunotherapy, | 174 |
| abstract_inverted_index.individualized | 293 |
| abstract_inverted_index.characteristics | 31 |
| abstract_inverted_index.triple-negative | 2 |
| abstract_inverted_index.Progression-free | 90 |
| abstract_inverted_index.clinicopathological | 273 |
| abstract_inverted_index.platinum-containing | 172, 189 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5033087015 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| corresponding_institution_ids | https://openalex.org/I4210100830, https://openalex.org/I4210163399 |
| citation_normalized_percentile.value | 0.45062353 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |